Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 8/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9666093 | 0.98 | MEN1 (0.53) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL28686443 | 0.87 | NAAA (0.50) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL2532077 | 0.87 | NAAA (0.50) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL28265469 | 0.87 | NAAA (0.50) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL2532080 | 0.87 | NAAA (0.50) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL16370788 | 0.84 | CYP4F2 (0.46) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL25189076 | 0.82 | MEN1 (0.57) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL22748706 | 0.82 | CYP4F2 (0.76) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL18909478 | 0.82 | MEN1 (0.57) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL21060863 | 0.82 | CYP4F2 (0.76) | MEN1MAPTKMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313350-A1 | PROCESS FOR ISOLATION AND/OR PURIFYING OF GLYCOLIPIDS | AMPHISTAR BV (BE) | 2024-02-07 | — | — | EP | claimed |
| US-11576375-B2 | Dispersible herbicidal compositions and methods of use | AMVAC CHEMICAL CORPORATION (US) | 2023-02-14 | — | — | US | claimed |
| WO-2022207086-A1 | PROCESS FOR ISOLATION AND/OR PURIFYING OF GLYCOLIPIDS | BIO BASE EUROPE PILOT PLANT VZW (BE) | 2022-10-06 | — | — | WO | claimed |
| EP-3692981-B1 | TOPICAL COMPOSITION FOR USE IN THE TREATMENT OF PSORIASIS | CHEM CURE ASS LLC (US) | 2022-05-04 | — | — | EP | claimed |
| US-11260063-B2 | Method and compositions for treating psoriasis | CHEM-CURE ASSOCIATES LLC (US) | 2022-03-01 | — | — | US | claimed |
| EP-3692981-A1 | TOPICAL COMPOSITION FOR USE IN THE TREATMENT OF PSORIASIS | Anaplasi Pharmaceuticals LLC (US) | 2020-08-12 | — | — | EP | claimed |
| US-20200129529-A1 | METHOD AND COMPOSITIONS FOR TREATING PSORIASIS | ANAPLASI Pharmaceuticals, LLC (US) | 2020-04-30 | — | — | US | claimed |
| EP-3305299-B1 | METHOD AND COMPOSITIONS FOR TREATING PSORIASIS | ANAPLASI PHARMACEUTICALS LLC (US) | 2020-04-29 | — | — | EP | claimed |
| US-20200102255-A1 | NEW METHOD FOR FERTILIZING AGRICULTURAL SOIL | BASF CORPORATION | 2020-04-02 | — | — | US | claimed |
| US-20200068880-A1 | DISPERSIBLE HERBICIDAL COMPOSITIONS AND METHODS OF USE | AMVAC CHEMICAL CORPORATION | 2020-03-05 | — | — | US | claimed |
| US-20060216242-A1 | Suspending vehicles and pharmaceutical suspensions for drug dosage forms | DURECT CORPORATION | 2006-09-28 | — | — | US | claimed |
| US-20060193918-A1 | Solvent/polymer solutions as suspension vehicles | INTARCIA THERAPEUTICS, INC. | 2006-08-31 | — | — | US | claimed |
| EP-1689363-A2 | COMPOSITION AND DOSAGE FORM COMPRISING AN AMPHIPHILIC MOLECULE AS A SUSPENSION VEHICLE | ALZA CORPORATION (US) | 2006-08-16 | — | — | EP | claimed |
| WO-2006083799-A2 | SUSPENDING VEHICLES COMPRISING A HYDROPHILIC SOLVENT, A HYDROPHOBIC SOLVENT, A POLYMER AND THE SUITABLE PUMP-DRIVEN DOSAGE FORM | ALZA CORPORATION (US) | 2006-08-10 | — | — | WO | claimed |
| WO-2006083761-A2 | SOLVENT/POLYMER SOLUTIONS AS SUSPENSION VEHICLES | ALZA CORPORATION (US) | 2006-08-10 | — | — | WO | claimed |
| US-20050222002-A1 | Method for a semi-aqueous wash process | WHIRLPOL CORPORATION | 2005-10-06 | — | — | US | claimed |
| WO-2005048952-A2 | COMPOSITION AND DOSAGE FORM COMPRISING AN AMPHIPHILIC MOLECULE AS A SUSPENSION VEHICLE | ALZA CORPORATION (US) | 2005-06-02 | — | — | WO | claimed |
| US-20050112188-A1 | Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle | INTARCIA THERAPEUTICS, INC. | 2005-05-26 | — | — | US | claimed |
| WO-2001092025-A1 | PAINT COMPOSITION, PAINT SET AND DIGITAL PRINTING PROCESS | BECKER INDUSTRIAL COATINGS LIMITED (GB) | 2001-12-06 | — | — | WO | claimed |
| US-6294508-B1 | CUTTING OILS AND ABRASIVES | 3M INNOVATIVE PROPERTIES COMPANY | 2001-09-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11576375-B2 | Dispersible herbicidal compositions and methods of use | DDT, HDHD5, GMDS | MEN1 4577/4885MAPT 2249/4885KMT2A 1164/4885 |
| US-20050112188-A1 | Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle | ANXA6, SLC47A2, SLC47A1 | MEN1 3806/4885MAPT 1924/4885KMT2A 4622/4885 |
| US-20200068880-A1 | DISPERSIBLE HERBICIDAL COMPOSITIONS AND METHODS OF USE | DDT, HDHD5, GMDS | MEN1 4577/4885MAPT 2249/4885KMT2A 1164/4885 |
| US-20060216242-A1 | Suspending vehicles and pharmaceutical suspensions for drug dosage forms | ABCB11, F12, PF4 | MEN1 1225/4885MAPT 2537/4885KMT2A 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.